FGFR1 inhibitor-10

Cat. No.:	HY-156019
CAS No.:	2426769-76-6
Molecular Formula:	$C_{26}H_{30}F_3N_7O_2S$
Molecular Weight:	561.62
Target:	FGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 14.29 mg/mL (25.44 mM; ultrasonic and warming and adjust pH to 2 with 1M HCl and heat to 80°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7806 mL	8.9028 mL	17.8056 mL
	5 mM	0.3561 mL	1.7806 mL	3.5611 mL
	10 mM	0.1781 mL	0.8903 mL	1.7806 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1.43 mg/mL (2.55 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 1.43 mg/mL (2.55 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 1.43 mg/mL (2.55 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC_{50}: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect[1].

IC_{50} & Target

FGFR1

REFERENCES

[1]. Li YL, et al. Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme. Eur J Med Chem. 2023 Nov 15;260:115764.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA